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Thymic epithelial tumors represent a wide range of anatomical, histological, clinical, and molecular malignant entities, which may be aggressive and difficult to treat.1 The man-
agement of thymic tumors is a paradigm of cooperation between clinicians, surgeons, and 
pathologists, from establishing the diagnosis to organizing the therapeutic strategy, as well as 
the follow-up of patients.1 As other rare cancers, thymic tumors, beyond their actual low fre-
quency, have been marked for long by the absence of comprehensive epidemiological data, 
the low number of biological and clinical research initiatives, and the lack of therapeutic 
recommendations.2 From 1989 to 2009, more than 75% of indexed publications on thymic 
malignancies were single case reports, whereas less than 5% were reporting on cohorts of 
100 or more patients.2 In the routine practice setting, personalization of care inherent to the 
rarity of the disease has mostly been based on historical, often preconceived representations, 
rather than evidence-based data. No randomized trial has ever been conducted in the field.
As a constant feature of rare tumors, collaboration may make a success, and thymic 
tumors represent a model of incremental effort in this setting. The International Thymic 
Malignancy Interest Group is an academic society that, starting 2010, built infrastruc-
tures to make multidisciplinary collaboration happen worldwide.3 The adoption of consen-
sual guidelines and definitions, released in a 2011 supplement of the Journal of Thoracic 
Oncology,4 made sense to improve the consistency of clinical approaches and research 
metrics. Meanwhile, the clarification of the World Health Organization histopathological 
classification through the identification of major and minor morphological and immuno-
histochemistry criteria by a multidisciplinary group where nonpathologists were included, 
now allows better diagnosis reproducibility of each subtype of thymic epithelial tumor.5
Ultimately, the next increment had to be the reassessment of staging, an even more 
clinically relevant prerequisite for the management of patients. In the setting of malig-
nancies, especially thymomas, with a propensity toward level-by-level local rather than 
regional or systemic invasion, the challenge was the development of a one-fit-all tumor, 
node, metastasis (TNM)-based approach. Proposals for such staging system were just 
released in the last supplement of the Journal,6 based on a retrospective database of more 
than 10,000 cases analyzed by the International Association for the Study of Lung Cancer 
Staging and Prognostic Factors Committee.6 Obviously, some criticisms may be raised, as 
reported by the authors, including the major surgical orientation of the database, and the 
use of overall survival as a primary end point, when thymic tumors often present with mul-
tiple episodes of recurrence, usually requiring multidisciplinary management in the setting 
of chemo- and radio-sensitive tumors; postoperative radiotherapy may then have favorably 
influenced the outcome of subsets of patients with certain anatomical features, such as 
pericardium invasion, then falsely considered as being associated with a better prognosis. 
Moreover, complete resection per se has been demonstrated to be the strongest prognostic 
factor in thymic tumors, beyond stage and histology.7 Ultimately, contrary to the majority 
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of frequent cancers, death is related to tumor progression only 
in 50% of cases.8
Taking into account the histopathological heterogeneity 
of thymic epithelial tumors is actually mandatory consider-
ing the above points, which better fit in with thymomas rather 
than thymic carcinomas. The series of 121 thymic carcinomas 
from Memorial Sloan Kettering Cancer Center, published in 
this issue of the Journal, clearly stresses the relevance of the 
tumor, node, metastasis approach for this subset of tumors9; 
among Masaoka stage IVB tumors, only lymph node invasion 
was associated with a better prognosis (5-year overall survival 
of 24 versus 7% in case of systemic metastases), as well with 
an eligibility for surgical resection (76% versus 9% in case of 
distant metastases).9 This finding strongly supports the use of 
tumor, node, metastasis-based staging for thymic carcinomas.
After all, even if the predictive relevance of staging to 
drive treatment strategy—actually mostly based on resect-
ability of the tumor—still remain to be assessed, the unprece-
dented effort led by International Thymic Malignancy Interest 
Group and International Association for the Study of Lung 
Cancer provide clinicians with reliable data regarding the out-
come of patients. Personalized decision making then becomes 
a reality, for example, in the setting of postoperative strategy, 
a situation where no prospective data have been reported.10 
Assessing the risk of tumor recurrence of an individual patient 
based on the anatomical extent and the histology of the tumor 
is now possible with the publication of these articles.
Personalization is even more the mainstay of the man-
agement of patients with advanced and recurrent thymic 
tumors; again, the limited amount of data contrasts with the 
frequency of the condition that surgically oriented databases 
may not catch. Again resection plays a major role part of a 
multimodal approach; in the Memorial Sloan Kettering Cancer 
Center series of thymic carcinomas, multimodal approach was 
required in more than 50% of cases.9 In the Italian series of 
81 patients with recurrent thymoma that is reported by Sandri 
et al.9 in this issue of the Journal, 25% of patients received 
chemotherapy and/or radiotherapy in a perioperative setting.
Overall, a challenge in recurrent thymomas is repre-
sented by the opportunity of achieving prolonged survival 
through optimized personalized management of each single 
recurrence episode—a paradigm typical of precision medicine 
in the setting of molecularly defined malignant entities. As 
Sandri et al. report, the 5-year survival rates after initial thy-
mectomy and after complete re-resection were 95% and 85%, 
respectively.11 Progress has to be made to understand what is 
the best management in this setting, highlighting the need to 
have a complete follow-up of patients in ongoing prospec-
tive databases, beyond the prism of initial surgical treatment. 
Whether staging is still relevant at the time of recurrence is one 
question. Understanding the mechanisms of thymoma recur-
rence may even more provide with insights in the pathogenesis 
of the disease. As discussed by Sandri et al., recurrence may 
result from tumor remnants (as suggested by the major prog-
nostic role of R0 resection), as well as the emergence of more 
aggressive subclones. Interestingly, an upgrade in the World 
Health Organization class was found in 41% of patients of this 
series, without any significant influence on outcome.
In the setting of multiple episodes requiring mul-
timodal approach, personalization of the treatment of 
advanced thymic malignancies requires a clear-cut definition 
of the intent—part of multimodal approach or definitive— as 
well as the setting—initial or recurrent episode—and the 
objective – curative  aiming at increasing survival, or palliative 
to controlthe tumor burden – of any therapeutic  intervention.12 
The third article on thymic malignancies published in this 
issue of the Journal reports on the results of a phase II trial 
assessing carboplatin and amrubicin in 51 Japanese patients 
with advanced thymic tumors.13 The objective response rate 
and the median progression-free and overall survival were 
30%, 7.6, and 27 months in the thymic carcinoma group, and 
17%, 7.6, and 58 months in the thymoma group, respectively, 
further highlighting the relatively good prognosis of thymic 
tumors even in the setting of unresectable disease.
Precision medicine approaches based on the identifica-
tion of oncogenic drivers predicting the efficacy of targeted 
agents remain to be developed in thymic tumors, despite 
significant efforts to dissect the molecular pathways of the 
disease.14,15 v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog (KIT) activating mutations have been 
observed in a subset of thymic carcinomas, and a pragmatic 
approach would be to recommend KIT genotyping in clini-
cal practice; such approach is, however, hampered by the 
observation that multikinase KIT inhibitors may be effective 
in advanced thymic tumors in the absence of such mutation, 
possibly through their antiangiogenic properties.16 Another 
approach is to promote the enrollment of patients with refrac-
tory thymic tumor in phase I trials, what may lead to identify 
new molecular pathways of therapeutic interest, such as mam-
malian target of rapamycin (mTOR).17 Ultimately, patients may 
be enrolled in ongoing basket trials that use high-throughput 
genome analysis to drive the use of multiple inhibitors of spe-
cific molecular pathways.
Along with the large variety of questions relative to 
the treatment strategy, thymic tumors represent a model of 
diagnostic and therapeutic implementation and achievement; 
ongoing research efforts require the mobilization of the global 
thoracic oncology community to gain a better knowledge and 
understanding of the disease, including the identification of 
relevant molecular information. Meanwhile, the routine man-
agement of patients with thymic tumors commits us to per-
sonalized medicine approaches based on available data from 
large cohorts of patients, laying the bases for multidisciplinary 
discussion.
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